- Home
- FUN vs OGN Comparison
FUN vs OGN Comparison
Compare FUN & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FUN | OGN |
|---|---|---|
| Founded | 1983 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2023 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FUN | OGN |
|---|---|---|
| Price | $17.16 | $7.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 4 |
| Target Price | ★ $27.08 | $11.75 |
| AVG Volume (30 Days) | 1.8M | ★ 4.3M |
| Earning Date | 05-25-2026 | 05-14-2026 |
| Dividend Yield | N/A | ★ 1.11% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.72 |
| Revenue | $3,100,289,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $3.93 | N/A |
| Revenue Next Year | $4.00 | $1.65 |
| P/E Ratio | ★ N/A | $10.01 |
| Revenue Growth | ★ 14.45 | N/A |
| 52 Week Low | $12.51 | $6.18 |
| 52 Week High | $41.56 | $15.88 |
Technical Indicators
Market Signals| Indicator | FUN | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.63 | 40.01 |
| Support Level | $14.70 | $6.85 |
| Resistance Level | $18.66 | $7.74 |
| Average True Range (ATR) | 1.15 | 0.36 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 53.71 | 40.52 |
Price Performance
Historical ComparisonAbout FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.